Editing
Kidney Cancer: Pathology
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== <span style="color:#ff0000">Subtypes</span> === {| class="wikitable" |'''<span style="color:#ff0000">Histology</span>''' |'''<span style="color:#ff0000">Characteristics</span>''' |'''<span style="color:#ff0000">Familial form and genetic factors</span>''' |- |'''<span style="color:#ff0000">Clear cell RCC (ccRCC)</span>''' '''<span style="color:#ff0000">(70-80%, most common)</span>''' |'''<span style="color:#ff0000">Originates from proximal tubule</span>''' '''<span style="color:#ff0000">Prognosis generally worse compared to papillary or chromophobe</span>''' '''Responds to systemic therapy''' |'''<span style="color:#ff0000">von Hippel-Lindau disease</span>''' '''Chromosome 3p deletions''' (VHL inactivation by mutation or promoter hypermethylation occurs in 70-90% of clear cell renal tumors) |- |'''Multilocular cystic''' '''ccRCC''' '''(uncommon)''' |'''Almost uniformly benign clinical behavior''' |'''Identical to ccRCC''' |- |'''<span style="color:#ff0000">Papillary RCC</span>''' '''<span style="color:#ff0000">(10-15%, 2nd most common)</span>''' |'''<span style="color:#ff0000">Originates from proximal tubule</span>''' '''<span style="color:#ff0000">Commonly multifocal</span>''' '''<span style="color:#ff0000">Common in ESRD and acquired renal cystic disease</span>''' '''<span style="color:#ff0000">Type 1: good prognosis</span>''' '''<span style="color:#ff0000">Type 2: worse prognosis</span>''' '''Grade may be of greater prognostic significance than type 1 vs. 2''' '''<span style="color:#ff0000">Current systemic therapies are ineffective against papillary RCC</span>''' Papillary adenomas are small (β€5mm) tumours that resemble papillary RCC under the microscope, are often well encapsulated and low grade, commonly found at autopsy, possess many of the same genetic alterations found in larger papillary RCCs, but are benign neoplasms |'''<span style="color:#ff0000">Type 1: Hereditary papillary RCC (HPRCC) syndrome</span>''' '''<span style="color:#ff0000">Type 2: Hereditary leiomyomatosis and RCC syndrome (HLRCC)</span>''' '''Trisomy of chromosomes 7 and 17 and loss of the Y chromosome.''' |- |'''<span style="color:#ff0000">Chromophobe RCC</span>''' '''<span style="color:#ff0000">(3-5%)</span>''' |'''<span style="color:#ff0000">Originates from</span>''' intercalated cells of '''<span style="color:#ff0000">distal tubule/collecting duct</span>''' '''Stains positive for Hale colloidal iron''' '''<span style="color:#ff0000">Generally good prognosis</span>''', compared to clear cell and papillary * Rates of disease-specific (recurrence, metastasis, or death due disease) events following nephrectomy:[https://pubmed.ncbi.nlm.nih.gov/21602658/] ** 5 years: 3.7% ** 10 years: 6.4% * Features associated with disease-specific events (4):[https://pubmed.ncbi.nlm.nih.gov/21602658/] *# Tumour size *# Small-vessel invasion *# Sarcomatoid features *# Microscopic necrosis ** pT stage or nodal metastasis tended to show some association, without reaching statistical significance |'''<span style="color:#ff0000">Commonly seen Birt-Hogg-DubΓ© syndrome;</span> most cases are sporadic''' |- |'''<span style="color:#ff0000">Collecting duct carcinoma (<1%)</span>''' |'''<span style="color:#ff0000">Originates from collecting duct</span>''' '''Stains positive with Ulex europaeus lectin''' '''Poor prognosis;''' most reported cases have been high grade, advanced stage, and unresponsive to conventional therapies '''May share features in common with urothelial carcinoma;''' '''advanced collecting duct carcinoma may respond to cisplatin or gemcitabine-based chemotherapy''' |Unknown Multiple chromosomal losses |- |'''<span style="color:#ff0000">Renal medullary carcinoma</span> (rare)''' |'''<span style="color:#ff0000">Originates from collecting duct</span>''' '''Dismal prognosis'''; '''many cases are both locally advanced and metastatic at the time of diagnosis''' |'''<span style="color:#ff0000">Associated with sickle cell trait (NOT disease);</span>''' typically diagnosed in young African-Americans |- |'''Unclassified RCC''' '''(1%-3%)''' |'''Origin not defined''' '''Poor prognosis''', most are poorly differentiated and are associated with a highly aggressive biologic behavior |Unknown |- |'''RCC associated with Xp11.2''' '''translocations/TFE3''' '''gene fusions (rare)''' |'''Occurs in children and young adults;''' 40% of pediatric RCC Prognosis similar to ccRCC |Various mutations involving chromosome Xp11.2 resulting in TFE3 gene fusion |- |Post-neuroblastoma RCC (rare) |Occurs exclusively in children with prior neuroblastoma |Unknown |- |Mucinous tubular and spindle cell (rare) |Favorable prognosis |Unknown |}
Summary:
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
UrologySchool.com:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
Edit source
View history
More
Search
Navigation
Main page
Clinical Tools
Guidelines
Chapters
Landmark Studies
Videos
Contribute
For Patients & Families
MediaWiki
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information